Articles from Newman Ferrara LLP

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of WM Technology, Inc. (“WM Technology” or the “Company”) (NASDAQMAPS) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of TPG, Inc. (“TPG” or the “Company”) (NASDAQTPG) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Empire Petroleum Corporation (“Empire” or the “Company”) (NYSEEP) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQZNTL) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Bridger Aerospace Group Holdings, Inc. (“Bridger” or the “Company”) (NASDAQBAER) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP today announced that a coalition of four congregations of Catholic Sisters represented by the firm filed a stockholder derivative lawsuit naming officers and directors of Smith & Wesson Brands Inc. (“Smith & Wesson” or the “Company”) for wrongdoing related to the marketing and sale of AR-15-style assault weapons. The suit, filed in the Eighth Judicial District Court, Clark County, Nevada, alleges that the defendants breached their fiduciary duty to the Company and its stockholders by knowingly and intentionally violating federal, state, and local laws, thereby exposing the Company to significant liability.

Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life Sciences Corp. (NASDAQATNF) (the “Merger”) that was completed on November 6, 2020.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQZNTL) (“Zentalis” or the “Company”). The investigations concern whether certain of the Zentalis’ officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQTIL) (“Instil” or the “Company”). The investigations concern whether certain of the Instil’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQSNSE) (“Sensei” or the “Company”). The investigations concern whether certain of the Sensei’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Passage Bio, Inc. (NASDAQPASG) (“Passage” or the “Company”). The investigations concern whether certain of the Passage’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of PTC Therapeutics (NASDAQPTCT) (“PTC” or the “Company”). The investigations concern whether certain of the Company’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of PTC’s business practices.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of 3M Company (NYSEMMM) (“3M” or the “Company”). The investigations concern whether certain of 3M’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed 3M; and (iii) failing to provide sufficient oversight of the Company’s business practices.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Smith & Wesson Brands, Inc. (NASDAQSWBI) and Sturm, Ruger & Company, Inc. NYSE:RGRNYSERGR)

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQSRNE) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of CME Group Inc. (“CME” or the “Company”) (NASDAQCME) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).